title: [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine].
abstract: Forty patients with advanced lung cancer who had received chemotherapy containing cisplatin (80 mg/m2) were accrued for a randomized controlled trial to evaluate the additional effect of prochlorperazine on the combination of high-dose metoclopramide and dexamethasone for the treatment of acute cisplatin-induced emesis. The effect of intravenous metoclopramide and dexamethasone in emesis occurring more than 24 hours after cisplatin administration was also evaluated. Excellent emetic control (no emesis during 24 hours after cisplatin administration) was achieved in 70% (14/20) and 76% (16/21) of the patients who received the combination of prochlorperazine, metoclopramide and dexamethasone and the combination of metoclopramide and dexamethasone, respectively. The overall toxicities associated with both regimens were not serious and were similar. Patients treated with metoclopramide and dexamethasone on days 2-7 experienced less delayed emesis, nausea and anorexia compared with those treated with a placebo (delayed emesis, 25% versus 50%, respectively, p = 0.105; more than 4 days of nausea, 10% versus 35%, respectively, p = 0.059; less than 3 days of anorexia, 80% versus 50%, respectively, p = 0.048). It was concluded that metoclopramide and dexamethasone showed an excellent antiemetic effect on acute drug-induced emesis, as well as on delayed emesis, induced by cisplatin.
authors.affiliation: Dept. of Internal Medicine, National Cancer Center Hospital, Tokyo.
authors.forename: S
authors.initials: S
authors.lastname: Nino
authors.forename: H
authors.initials: H
authors.lastname: Umehara
authors.forename: I
authors.initials: I
authors.lastname: Inoue
authors.forename: T
authors.initials: T
authors.lastname: Tamura
authors.forename: Y
authors.initials: Y
authors.lastname: Sasaki
authors.forename: M
authors.initials: M
authors.lastname: Sakurai
authors.forename: T
authors.initials: T
authors.lastname: Shinkai
authors.forename: K
authors.initials: K
authors.lastname: Eguchi
authors.forename: N
authors.initials: N
authors.lastname: Saijo
authors.forename: K
authors.initials: K
authors.lastname: Suemasu
mesh_terms: D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008787:Metoclopramide / Q000008:administration & dosage*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D011346:Prochlorperazine / Q000008:administration & dosage*; D011897:Random Allocation; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D003907:Dexamethasone; D008787:Metoclopramide; D002945:Cisplatin; D011346:Prochlorperazine